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htcense.Abstract Introduction: The sensitivity of conventional cytology for the detection of malignant
cells in pleural effusion is insufﬁcient. Since survivin is frequently overexpressed in lung cancer, it
might play a role in oncogenesis and progression of the tumor.
Objective: To evaluate diagnostic value of survivin mRNA expression in lung cancer with pleural
effusion.
Patients and methods: Sixty-ﬁve pleural ﬂuid specimens were collected from lung cancer patients
(group I). Twenty benign pleural ﬂuid specimens were also collected (group II), considered to be
control group, and this group was classiﬁed into transudate and exudate according to Light’s cri-
teria. Real time Polymerase chain reaction (RT-PCR) was performed to detect the survivin mRNA
expression in the pleural ﬂuid specimens. The sensitivity, speciﬁcity and accuracy were calculated by
using receiver operating characteristic (ROC) analysis.tive Oncology Group; LDH,
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104 G.H. Abo El-Magd et al.Results: Sixty-ﬁve pleural ﬂuid specimens from lung cancer patients were tested by RT-PCR,
only 30/65 (46%) had positive cytology. The positive rate of survivin mRNA expression in maligant
pleural effusion (63/65; 95.38%) was much higher than that in the pleural effusion with benign dis-
ease (4/20; 20%, P< 0.01). Twenty-seven cancer patients were negative for cytology and 24/27
were positive for survivin mRNA expression. The sensitivity, speciﬁcity and accuracy of survivin
were 89.5%, 50%, 73.1% for diagnosing malignant pleural effusion.
Conclusions: The detection of survivin by RT-PCR seems to be a promising assay to diagnose
malignant pleural effusions, using the appropriate cut-off point, survivin mRNA has a signiﬁcant
role in differentiating benign from malignant pleural effusion.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Pleural effusions are common complications of a wide variety
of diseases. The initial diagnostic approach includes thoraco-
centesis and cytological, histological and biochemical examina-
tions [1]. However, the sensitivity of these noninvasive
techniques is only 40–70% [2]. The sensitivity of conventional
cytology for the detection of malignant cells in pleural effusion
is insufﬁcient [3]. Differentiating between malignant pleural
effusion (MPE) and non-MPE often has important therapeutic
implications [4].
The limitations in cytology must be overcome by other
techniques and markers. Survivin is an inhibitor of pro-
grammed cell death, survivin mediates suppression of apopto-
sis by inhibition of the caspases 3 and 7, the terminal effectors
in apoptotic protease cascades [5]. Survivin is expressed in the
G2-M phase of the cell cycle and its interaction with the mito-
tic spindle apparatus has been reported to be essential for anti-
apoptotic function [6]. The survivin promotor was highly
active in human tumor cells, but not in normal cells, and up-
regulated by hypoxia in tumor [7].
Survivin is up-regulated in most cancers, including lung,
breast, esophagus, stomach, colon, pancreas, bladder, uterus,
ovary and liver carcinomas, soft tissue sarcomas, and leuke-
mias [8].
In previous publications, survivin in urine has high speciﬁc-
ity and sensitivity for diagnosing bladder cancer [9]. Since sur-
vivin is frequently overexpressed in lung cancer, it might play a
role in oncogenesis and progression of the tumor. It inhibits
apoptosis and promotes mitosis [10]. Dong et al. [11] reported
on survivin detection in sputum samples and pleural effusions
as a new diagnostic approach for lung cancer.Aim of the work
This study aimed to evaluate diagnostic value of survivin
mRNA expression in pleural effusions from lung cancer
patients.Patients and methods
This work was carried out on 85 patients with pleural effusion
attended in Chest and Clinical Oncology Departments, Tanta
University Hospital during the period from October 2009 to
January 2011. This study was performed in compliance with
ethical rules at our locality.Patients
Patients with pleural effusion routinely underwent diagnostic
thoracocentesis to obtain pleural ﬂuid specimens for cell count;
the measurement of total protein, lactate dehydrogenase
(LDH) and cytological examination.
The effusions were classiﬁed as benign or malignant accord-
ing to clinical and pathological diagnoses. Sixty-ﬁve pleural
ﬂuid specimens were collected from patients with newly diag-
nosed lung cancer (group I). Twenty benign pleural ﬂuid spec-
imens were also collected (group II), considered to be control
group, and this group was classiﬁed into transudate and exu-
date according to Light’s criteria [12].
Malignant pleural effusion was diagnosed if malignant cells
were found on cytological examination. Paramalignant effu-
sions were exudative effusions that are not the direct result
of neoplastic involvement of the pleura but related to the pri-
mary tumor.
Parapneumonic effusions were associated with an acute feb-
rile illness and cough. Chest radiograph revealing pulmonary
inﬁltrates with response to antibiotic treatment. A diagnosis
of congestive heart failure (CHF) was made by ﬁndings of
an enlarged heart, peripheral edema and absence of manifesta-
tions of malignancy or manifestations associated with an
inﬂammatory process.
Real time-polymerase chain reaction (RT-PCR) was per-
formed to detect survivin mRNA expression in the pleural
ﬂuid specimens.
Assessment of survivin gene expression by real time PCR
RNA extraction [13]
RNA was isolated from the cells using total RNA isolation kit
(gentra systems, USA) and cDNA synthesis was performed
with a random hexamer from the High-Capacity cDNA Kit
(Applied Biosystem, USA) prim RNA samples for reverse
transcription (RT) using MultiScribe reverse transcriptase
enzyme.
DNA ampliﬁcation for survivin by real time PCR [14]
Each sample or l of TaqManhl was mixed with 25hstanderd
(5A universal PCR Master Mix (1· Taqman Buffer,
3.5 mmol/l MgCL2, 200 mmol/l dATP, 200 mmol/l dCTP,
200 mmol/1 dGTP, 200 mmol/l dUTP, 0.5 U AmpErase Uracil
N-glycosylase (UNG) and 1.25 U of AmpliTaq Gold). (Applied
Biosystem USA), 2.5 ll of Primer-Probe mix, 17.5 ll of RNase
free water (Total volume 50 ll). Survivin gene Primers were,
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Reverse primer: (50-ATGAAGCCAGCCTCGGC-30)
Survivin probe: (50-CAAGGACCACCGCATCTCTA-
CATTCAAACCGCATCT-TACATTCAAGA-30).
The tubes were placed in thermal cycler of the Gene Amp
5700 sequence detector. The PCR conditions were 2 min at
50 C, followed by 45 cycles for 15 s at 95 C, and 1 min at a
primer-speciﬁc annealing extension temperature (60 C).
Experiments were performed in duplicate. Each PCR run in-
cluded six standards. At the end of the PCR run, this data is
analyzed by the GeneAmp 5700 SDS software. Samples of
known DNA concentration were run as standards at the same
time as unknown samples, so the concentrations of the un-
known samples can be determined.
Statistical analysis
Statistical presentation and analysis of the present study was
conducted, using the median, standard error, unpaired student
t-test, analysis of variance [ANOVA] test, Mann–Whitney or
Kruskal–Wallis by SPSS V18. The sensitivity, speciﬁcity and
accuracy were calculated by using receiver operating character-
istic (ROC) analysis.
Results
Real time-polymerase chain reaction (RT-PCR) was per-
formed to detect the survivin mRNA expression in the pleural
ﬂuid specimens. The results were compared with their cytolog-
ical examinations.
Group I (Lung cancer related pleural effusion): It included
65 patients, 25 (38.46%) females and 40 (61.54%) males, the
mean value of age was (62.17 ± 5.53) years. They were
thirty-eight (58.46%) malignant pleural effusion with positiveTable 1 Characteristics of patients in the studied groups.
Group I n (%) Group
Exuda
Age (year)
Range 47–73 19–55
Mean ± SD 62.17 ± 5.53 38.69
Surviving
Positive n (%) 62 (95.38%) 4 (30.
Negative n (%) 3 (4.61%) 9 (69.
Median IQR 3.25 · 105 (2.92 · 106) 0.3(1.
Sex
Female n (%) 25 (38.46%) 5 (38.
Male n (%) 40 (61.54%) 8 (61.
Aetiology
TB n (%) 0 8 (61.
Pneumonia n (%) 0 3 (23.
Pulmonary embolism n (%) 0 2 (15.
Congestive heart failure n (%) 0 0
Liver cirrhosis n (%) 0 0
MPE n (%) 38 (%) 0
Para-MPE n (%) 27 (%) 0
IQR: inter quartile range.
*P< 0.05.
** P< 0.01.cytology and twenty-seven patients (41.54%) para-malignant
pleural effusion with negative cytology (Table 1).
Group II (Benign pleural effusion group): It included 20 pa-
tients, there were 8 females and 12 males, they were classiﬁed
according to etiology into (Table 1):
– Exudative effusion (group IIA): 8 (61.54%) patients with
TB, 3 (23%) patients with pneumonia, 2 (15.38%) patients
with pulmonary embolism.
– Transudative effusion (group IIB): 3 (42.85%) patients with
congestive heart failure and 4 (57.14%) patients with liver
cirrhosis.
Sixty-ﬁve pleural ﬂuid specimens from lung cancer patients
(group I) were tested for survivin expression by RT-PCR, only
38/65 (58.46%) had positive cytologic examinations, whereas
62/65 (95.38%) were positive for survivin mRNA. Twenty-se-
ven (41.54%) lung cancer patients were negative for cytologic
examination and 24 out of these 27 specimens were positive for
survivin mRNA expression. Twenty pleural ﬂuid specimens
with benign disease were also studied for survivin mRNA
expression (group II), only 4/20 tuberculus cases were positive
for survivin mRNA expression (20%). The positive survive
expression was signiﬁcantly higher in group I compared to
group IIA and IIB (ANOVA= 45.4, p< 0.01) (Table 1).
The median value of survivin mRNA was (3.25 · 105), (0.3)
and (0) in group I, IIA and IIB respectively. There was signif-
icant statistical difference in the median value of survivin
mRNA among studied groups (ANOVA test = 45.4, p
< 0.01) (Table 1 and Fig. 1).
There was no statistical difference in pleural effusion WBC,
glucose, protein and LDH in the two studied groups (Table 2).
Cut-off value of survivin mRNA was determined by the
maximum sum of sensitivity and speciﬁcity, The cut-off valueII n (%) ANOVA test P-value
te (IIA) Transudate (IIB)
47–63 67.4 0.00**
± 11.29 54.29 ± 5.82
76%) 0 45.4 0.00**
23%) 7 (100%)
35) 0(0.2)
46%) 3 (42.86%) 0.052 0.974
54%) 4 (57.14%)
54%) 0 20.0 0.00**
08%) 0
38%) 0
3 (42.86%)
4 (57.14%)
0
0
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Figure 1 Survivin mRNA in the studied groups.
Table 2 Characteristics of pleural effusion in the two studied
groups.
Pleural ﬂuid Group I Group II T-test
t P-value
WBC (ml) 1752.1 ± 3134.2 2567.2 ± 2357.3 1.072 0.286
Glucose 112.4 ± 42.3 110.9 ± 89.3 0.104 0.917
Protein (g/dl) 4.19 ± 0.89 4.56 ± 1.1 1.536 0.128
LDH (IU/l) 920.5 ± 883.4 1048.3 ± 799.4 0.578 0.564
WBC: White blood cells, LDH: lactate dehydrogenase.
Figure 2 ROC curves for survivin expression classiﬁcation
(AUROC curve is 0.731 (73.1%), *p< 0.001) in group I. The
plot was constructed by computing the sensitivity vs. (1h
speciﬁcity) for the different possible cutoff points of the survivin
mRNA.
Table 3 Cutoff value, sensitivity, speciﬁcity, PPV, NPV and
accuracy of survivin mRNA in group I.
Cutoﬀ value
(%)
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Accuracy
>5500 89.5 50.0 73.9 75.0 0.731
PPV: positive predictive value, NPV: negative predictive value.
Figure 3 Survivin mRNA expression in group I. Box plot
showing expression levels of survivin mRNA in positive and
negative pleural effusion cytology above cut off value.
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(5.5 · 1000). Analysis of the ROC curves for the survivinmRNA expression in the pleural ﬂuid is shown in Fig. 2. Pleu-
ral ﬂuid survivin mRNA had large area under the ROC curve
(0.731) suggesting that it was accurate in differentiating neo-
plastic from benign exudative effusions. The sensitivity, speci-
ﬁcity and accuracy were 89.5%, 50%, 73.1% of survivin for
diagnosing MPE (Table 3). The sensitivity, speciﬁcity, and
accuracy were 40%, 93.7%, 67.8% of cytology for diagnosing
MPE (see Fig. 3).
Correlation between pleural effusion survivin and selected
univariate parameters
There was signiﬁcant correlation between survivin mRNA
expression and cytology, stage of the tumor, histological sub-
type and ECOG performance status (p< 0.05), while no sig-
niﬁcant correlation was found between age, sex and survivin
expression (p> 0.05) (Table 4).
Discussion
Pleural ﬂuid cytology remains the most speciﬁc, relatively sen-
sitive and inexpensive test and should be an investigation of
ﬁrst choice. If the ﬁrst pleural ﬂuid sample is negative by cyto-
logical examination, at least two other samples should be
examined for the presence of malignant cells. Pleural biopsy
should be attempted at the same time. If both results are neg-
ative, tumor markers should then be tested [15].
Survivin is expressed in a vast majority of human cancers
[16] and is one of the key factors conferring and maintaining
resistance to apoptosis [17]. Some authors studied 64 lung can-
cer patients who show a signiﬁcant up-regulation of survivin
Table 4 Correlation between pleural effusion survivin and selected univariate parameters.
Survivin
Median IQR Mean rank Z or X2 P-value
Age
<65 5.7 · 105 3.39 · 106 31.654 0.087z 0.930
>65 2.5 · 105 2.29 · 106 31.239
Sex
Female 4.7 · 104 3.36 · 106 31.667 0.058z 0.954
Male 4.85 · 105 2.44 · 106 31.395
Cytology
Negative 3.08 · 104 9.78 · 105 26.16 2.40 0.016*
Positive 1.01 · 106 7.79 · 106 37.20
Stage
IIIA 5.5 · 103 5.68 · 105 30.640 6.153x 0.046*
IIIB 5 · 103 2.89 · 106 19.088
IV 7.65 · 105 3.21 · 106 28.750
Histology
Adenocarcinoma 9.3 · 105 3841750 34.040 12.293· 0.015*
Squamous 5.3 · 103 2.28 · 105 20.029
Large 4.66 · 105 4.44 · 106 32.000
Small 2.3 · 106 9.81 · 106 44.000
Undiﬀerentiated 1 · 106 44.500
Performance status ECOG
0 3.45 · 103 7.28 · 105 18.250 4.768x 0.092
1 6 · 104 3.29 · 106 31.477
2 8.6 · 105 5.83 · 106 37.692
Type of eﬀusion
MPE 9.6 · 105 6.94 · 106 36.78 2.89 0.004**
Para-MPE 7.5 · 103 9.01 · 105 23.15
X: Krouskal test (X2), Z: Mann–Whitney test, IQR: inter quartile range, ECOG: Eastern Cooperative Oncology Group.
* P< 0.05.
** P< 0.01.
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ing, some studies described a strong survivin mRNA up-regu-
lation in NSCLC [10,18]. There are few reports on survivin
expression in pleural effusions of cancer patients [19,20].
Some investigators stated that survivin is highly up-regu-
lated in malignancy and is involved in the critical determinants
of tumor progression such as evasion of apoptosis, increased
proliferation and angiogenesis, it is an attractive target for
new anti-cancer therapies [21].
In this study, sixty-ﬁve pleural ﬂuid specimens from lung
cancer patients were tested for survivin mRNA by RT-PCR,
only 38/65 (58.46%) had positive cytologic examinations, The
positive rate of survivin mRNA expression in maligant pleural
effusion (62/65; 95.38%) was much higher than that in the pleu-
ral effusion with benign disease (4/20; 20%, P< 0.01).
Twenty-seven cancer patients were negative for cytologic exam-
ination and 24/27 were positive for survivin mRNA expression.
The sensitivity, speciﬁcity and accuracy were 89.5%, 50% and
73.1% of survivin for diagnosing MPE and for cytology was
40%, 93.7% and 67.8% respectively.
Weikert et al. [22] detected survivin mRNA with bladder
cancer. In their study urinary survivin mRNA yielded a sensi-
tivity of 68.6% and a speciﬁcity of 100% for non-invasive
bladder cancer, while urine cytology only gave a sensitivity
of 31.4% and a speciﬁcity of 97.1%.Falleni et al. [23] quantiﬁed mRNA levels of the apoptosis
regulating genes; survivin (member of inhibitors of apoptosis),
Bcl-2 and Bax (members of the Bcl-2 family). They studied 22
non-neoplastic pleural samples, comprising normal and
inﬂammatory tissue specimens, and 42 pleural malignant mes-
otheliomas using real-time RT-PCR. Falleni et al. reported sig-
niﬁcantly increased levels of survivin mRNA in pleural
malignant mesotheliomas compared to normal/ﬁbrotic pleural
tissues.
Some authors investigated the expression of survivin pro-
tein in the malignant pleural effusions with lung adenocarci-
noma and 25 benign pleural effusions; the determination of
exfoliated cytology in malignant pleural effusions was also
set as a control. Although they studied the expression of sur-
vivin protein by immunocytochemistry and western blot,
their results were consistent with our study. They detected
that survivin protein expression in the malignant pleural effu-
sions was 81.6%, it was signiﬁcantly higher than that of
pleural effusion cytology (52.1%) and benign effusion (8%)
[24].
In the present study, there was signiﬁcant correlation be-
tween survivin mRNA expression and cytology, stage of the
tumor, histological subtype (p< 0.05), while no signiﬁcant
correlation was found between age, sex and survivin mRNA
expression (p> 0.05).
108 G.H. Abo El-Magd et al.Span et al. [25] reported that survivin mRNA was not cor-
related with patient age, nodal status, tumor size, histological
grade, and hormone receptor status in a breast cancer study.
In agreement with our ﬁndings, Zhang et al. [24] reported
that there were no relationship between age, sex and lymph
node metastasis or distant metastasis with malignant pleural
ﬂuid survivin expression.
Recently, some investigators studied 44 pleural effusion
specimens for survivin, CA125 and CEA to investigate the
diagnostic value of their combined detection for differentiating
benign from malignant pleural effusion and ascites. They con-
cluded that the combined detection of survivin, CEA and
CA125 in the ascites or pleural effusion may improve the po-
sitive rate of diagnosis of ascites and pleural effusion signiﬁ-
cantly [26].
Park and colleagues [27] studied pleural effusion samples
which were collected from 67 patients with MPE (58 lung can-
cers; 9 extrathoracic tumors), and from 68 patients with benign
conditions (31 with pneumonia; 37 with tuberculosis). Concen-
trations of pleural ﬂuid survivin, Cyfra 21-1, and carcinoem-
bryonic antigen (CEA) were measured by enzyme-linked
immunosorbent assay. Survivin, Cyfra 21-1, and CEA varied
in diagnostic accuracy for differentiating MPE from benign
pleural effusion by 67.5%, 68.3%, and 93.4%, respectively.
The diagnostic accuracy of survivin in our study was 73.1%
which is higher than that of the previous study, this can be ex-
plained by different method for assessment of survivin.
In conclusion, the ﬁndings of this study suggest that survi-
vin mRNA may be helpful in diagnosing MPE as a useful
adjuvant of cytology. Survivin mRNA expression has a signif-
icant role in differentiating benign from malignant pleural
effusion.
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